NCT05020964
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with central nervous system disease
https://ClinicalTrials.gov/show/NCT05020964